DEVELOPMENTAL MEDICO-LIFE-SCIENCES

ISSN (P): 3007-2786, (E): 3007-2794 DOI: https://doi.org/10.69750/dmls.02.06.0136

EDITORIAL Open Access

Advancing Personalized Medicine Through Biochemical Markers in Resource-Limited Settings: Balancing Innovation with Practicality

Naveed Shuja [1*]

1- Lahore Medical and Dental College (LM&DC) , Lahore, Pakistan.

Corresponding Author: Naveed Shuja, **Email**: rananaveedshuja@gmail.com, **Cell:** +92-3334205687

Keywords: Personalized care; Biomarkers; Low-resource; Precision medicine; Point-of-care; Equity.

Received: 08/02/2025
Revised: 17/05/2025
Accepted: 27/06/2025
Published: 30/06/2025

Personalized medicine an approach that tailors' disease prevention, diagnosis, and treatment to individual variability in genes, environment, and lifestyle has emerged as a transformative paradigm in global health. Central to this movement is the use of biochemical markers, ranging from genetic polymorphisms and proteomic profiles to simple, cost-effective assays such as HbA1c, C-reactive protein, and lipid subfractions. These markers hold the promise of guiding clinicians toward precision interventions, reducing therapeutic failures, and improving patient outcomes. Yet, in resource-limited settings, the path to implementing such innovations is fraught with both opportunities and challenges [1,2].

The Promise of Biochemical Markers: Biochemical markers serve as measurable indicators of physiological or pathological processes, offering a window into disease progression and therapeutic response. In oncology, markers such as HER2 and EGFR mutations have revolutionized treatment decisions, while in cardiology, troponins and natriuretic peptides guide early interventions. In diabetes care, HbA1c and adipokines like leptin and adiponectin refine risk stratification and management. For resource-limited countries, where healthcare infrastructure often struggles with overburdened systems and limited expertise, integrating such markers could bridge the gap between generalized care and truly individualized treatment [3,4].

Barriers in Resource-Limited Contexts: Despite the transformative potential, several barriers hinder widespread adoption. Advanced biomarker assays often require costly equipment, highly skilled laboratory personnel, and sustainable supply chains all of which may be constrained in low- and middle-income countries. Moreover, inequities in access, affordability, and awareness further limit patient benefit. For instance, while genomic sequencing may be routine in developed nations, even routine biochemical panels can be inaccessible for marginalized populations in rural Pakistan, Sub-Saharan Africa, or Southeast Asia. Without addressing these disparities, the promise of personalized medicine risks becoming a privilege rather than a right [5,6].

Striking a Balance: The question, therefore, is not whether resource-limited health systems can adopt personalized medicine, but how they can do so responsibly and sustainably. Practical strategies include prioritizing affordable, high-yield biomarkers that can be incorporated into existing clinical workflows. For example, point-of-care tests for HbA1c, CRP, or microalbuminuria are feasible in primary care centers and can meaningfully guide management decisions for diabetes and cardiovascular diseases. Local validation of biomarker utility is equally important contextualized studies ensure that markers developed in Western cohorts are relevant to the genetic, dietary, and environmental realities of South Asian or African populations [7].

Partnerships with global consortia, public–private collaborations, and technology transfer initiatives could enable capacity building. Furthermore, open-access data repositories and regional research collaborations may empower local scientists to innovate within their contexts,

producing context-specific panels of biochemical markers. A tiered implementation framework where basic biochemical assays form the foundation, with gradual scaling to advanced genomic platforms could allow health systems to advance while staying rooted in practicality [8-11].

Ethical and Equity Considerations: Ethical dilemmas inevitably accompany the implementation of personalized medicine in low-resource environments. The risk of deepening inequities is real: if advanced care is available only to the affluent, the very essence of "personalized" medicine is lost. Policymakers must therefore prioritize equitable access, subsidized testing, and inclusion of vulnerable groups in implementation strategies. Community engagement, transparency in communication, and integration of cultural values remain indispensable in ensuring that personalized medicine is not only innovative but also humane [12-15].

CONCLUSION

Personalized medicine through biochemical markers represents a frontier of hope, but its integration into resource-limited settings requires a pragmatic vision. By focusing on affordable, validated, and context-appropriate biomarkers, health systems can balance the ideals of innovation with the imperatives of equity and practicality. The true success of personalized medicine will not be measured by its sophistication in wealthy nations, but by its ability to transform health outcomes in the very regions where the need is greatest.

Conflict of Interest: The authors report no conflicts of interest.

Funding: No external funding was received for this study.

Acknowledgments: We gratefully acknowledge our colleagues and all study participants for their valuable contribution.

Authors' contributions: All authors reviewed and approved the final manuscript all contributed equally.

REFERENCES

1. Wojtas DS, et al. Personalised medicine implementation to the healthcare. J Pers Med. 2023;13(7):1145.
2. Maltsev D. Application of a personalised approach in clinical practice: a systematic review. J PMS. 2025;xx(x):xx–xx. doi:10.47310/jpms2025140602.
3. Passaro A, et al. Cancer biomarkers: emerging trends and clinical. Cell. 2024.
4. Ng KW, et al. Biomarkers and point of care screening approaches for the. Nat Med Commun. 2024.
5. Cao H. Advancing clinical biochemistry: addressing gaps and. Front Med. 2025.
6. Cockburn JG, et al. Integrative research: current trends and considerations for. Clin Biomark Res. 2025.
7. Tsimberidou AM, et al. Strategies to address the clinical practice gaps affecting. J Clin Oncol Pract. 2024.
8. Norris RP, et al. Are there socio-economic inequalities in utilization of. BMC Med. 2020;18:282.
9. Molla G. Synergy with multi-omics data generation, main hurdles. Biomark Insights. 2024;12(12):2750.
10. Marques L. Advancing precision medicine: a review of innovative in. Pharmaceutics. 2024;16(3):332.
11. Khan A. Genomic medicine and personalized treatment. J Genom Med. 2025.
12. Molla G. Revolutionizing personalized medicine: synergy with multi-omics. Transl Med Rev. 2024.
13. Lip S. Introduction to precision medicine. Prec Med J. 2025.
14. Sarátkar SY, et al. Digital twin for personalized medicine development. Front Digit Health. 2025.
15. Francisco KY, et al. Can personalized medicine coexist with health equity? Health Policy Technol. 2025.

This Article May be cited as: Shuja N. Advancing personalized medicine through biochemical markers in resource-limited settings: balancing innovation with practicality: affordable biomarkers for global health equity. *Dev Med Life Sci.* 2025;2(6):1-3. doi:10.69750/dmls.02.06.0136.